- Strategy
- Payers
- AI
- Cybersecurity
- Device Development
- Studies/Published Research
- Ethics
- Regulatory
- Digital Biomarkers
- Data Science
- Companion Diagnostics
- Clinical Care
- Digital Therapeutics
- Academic Research
- Virtual Reality
- RWE
- Digital Endpoints
- Medical Devices (Class II and Class III)
- Commercialization
- Clinical Trials
- Drug-Device Combinations
- SaMD
- Remote Patient Monitoring
- Patient Engagement
- Profiles/Q&A
Varian Receives Investigational Device Exemption for Cardiac Radioablation Clinical Trial
Trial will compare patients that undergo cardiac radioablation with Varian's CRA system vs. standard-of-care catheter ablation.
Varian, a Siemens Healthineers company, announced FDA IDE approval for its pivotal RADIATE-VTTM clinical trial. The RADIATE-VT trial will be an international, multi-center, randomized controlled trial to evaluate the safety and efficacy of cardiac radioablation (CRA) compared to repeat catheter ablation for patients with high-risk refractory ventricular tachycardia (VT).
Varian's CRA system received FDA Breakthrough Device designation in 2021, and is designed to provide non-invasive delivery of precisely targeted high-dose radiation, enabling ablation across the full thickness of the myocardium, which may offer the potential to improve control of the patient's VT compared to the current standard of care.
Read more about the clinical trial.
